ProSomnus signs business combination agreement with Lakeshore
The companies expect to receive a minimum additional $10m in equity from Lakeshore's trust account or a PIPE.

The companies expect to receive a minimum additional $10m in equity from Lakeshore's trust account or a PIPE.
The Simoa test can be used in conjunction with clinical, imaging and laboratory findings to identify patients with RRMS.
The study will evaluate the safety and performance of the new balloon guide catheter to treat acute ischemic stroke.
The device allows patients to self-inject TNF inhibitors automatically without measurement or preparation.
C2inform eliminates the need for patient-specific assay development and offers a rapid solution for cancer patients.
The disposable device needs no electromechanical pump, battery or canister and delivers advantages in ease of use.
The aura6000 System is designed to maintain the tongue’s muscle tone and features an implantable pulse generator.
Last year, Abilitech and the Praxis Spinal Cord Institute partnered to further scale the device for mass commercialisation.
In order to calculate the prothrombin time and international normalised ratio, the phone gathers two timestamps.